MLTX - CIK 0001821586
The table below shows MoonLake Immunotherapeutics's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $298.49M | $350.74M | $306.68M | $271.57M | $375.66M | $342.79M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $396.64M |
| $411.21M |
| $455.48M |
| $506.26M |
| $512.32M |
| $536.88M |
| Property, plant & equipment | $532.00K | $622.00K | $667.00K | $711.00K | $581.38K | $481.70K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $400.37M | $414.33M | $460.10M | $511.26M | $518.21M | $544.88M |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | $46.11M | $48.37M | $27.36M | $23.98M | $20.08M | $12.28M |
| Long-term debt | $99.02M | $73.74M | $73.38M | $73.02M | - | - |
| Total liabilities | $146.35M | $123.14M | $102.15M | $98.68M | $22.71M | $14.85M |
| Retained earnings | -$532.62M | -$400.49M | -$330.76M | -$275.54M | -$189.99M | -$154.60M |
| Total equity | $254.02M | $288.91M | $353.73M | $407.52M | $488.20M | $520.66M |